Generium, a Russian developer of biotechnological medicines, will supply its products to a number of countries of the Middle East and North Africa (MENA) region. The agreements were reached during the 12th Annual Investment Meeting in Abu Dhabi, RIA Novosti reports.
“We offer highly competitive drugs for the treatment of rare diseases, which [only] two or three companies in the world can produce. Today’s negotiations resulted in direct agreements on expanding the supply of Russian-made biotechnological drugs to a number of countries in the MENA region,” said Dmitry Kudlay, Vice President of the company.
At the end of 2022, the Expert Council of the Industrial Development Fund (IDF) approved a loan in the amount of 2 billion rubles to Generium-Next, an enterprise owned by AO Generium, under the Priority Projects program. The funds are intended for the construction of a facility to produce drugs for the treatment of asthma and rare diseases.
